Anastrozole

• ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz… Recruiting
  2023-508094-88-00 Phase III 1 country University Of Florence
• Trial that evaluates the interest of interruption versus maintaining the treatment of aromatase inhibitors in patients with metastatic low g… Recruiting
  2024-512629-97-00 Phase II 1 country Centre Leon Berard
• A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended
  2022-503001-38-01 Phase III 2 countries Novartis Pharma AG
• A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II… Ended
  2024-516530-36-00 Phase III 1 country Cancer Trials Ireland
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended
  2024-513540-29-00 Phase III 5 countries Alliance Foundation Trials LLC
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended
  2022-501024-20-00 Phase III 14 countries Astrazeneca AB
• Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended
  2024-514480-26-00 Phase II 1 country Unicancer
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended
  2022-500014-26-00 Phase III 8 countries F. Hoffmann-La Roche AG
• Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended
  2024-511209-49-00 Phase IV 1 country Universitaetsklinikum Ulm AöR
• Multi-drug treatment for breast cancer patients with brain metastases Ended
  2024-510703-11-00 Phase II 1 country Unicancer
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended
  2023-503990-39-00 Phase III 12 countries AstraZeneca AB
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended
  2023-503995-26-00 Phase III 13 countries AstraZeneca AB
• Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended
  2024-513005-31-00 Phase III 1 country Unicancer
• A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended
  2023-505223-31-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended
  2023-510357-42-00 Phase III 10 countries Novartis Pharma AG
• Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended
  2024-516204-42-00 Phase III 1 country BOOG Study Center B.V.
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended
  2023-509671-17-00 Phase III 16 countries Eli Lilly & Co.
• PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended
  2024-510704-37-00 Phase III 1 country Unicancer
• PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation … Ended
  2024-519019-32-00 Phase II 1 country Karolinska University Hospital
• "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone… Ended
  2024-515368-29-00 Phase III 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive N… Ended
  2024-516801-22-00 Phase III 1 country Cancer Trials Ireland
• A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended
  2022-503013-32-00 Phase II 7 countries ETOP IBCSG Partners Foundation
• DESTINY-Breast08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other thera… Ended
  2023-505690-33-00 Phase I (Other) 1 country Astrazeneca AB

Showing 25–47 of 47 trials